HEART: Pilot Randomized Controlled Trial
Key facts
- Where
- Rochester, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Saad OmarTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT07483177
- Record updated
- 8 June 2026
- Original description
The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.Read full original descriptionShow less
Hemodynamic Effects Of Aldosterone Receptor Blockade In Degenerative Thoracic Aortic Aneurysm: A Pilot Randomized Controlled Trial (HEART: Pilot RCT)
The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.
Inclusion: Adults ≥ 18 years old with dTAA of the aortic root and/or ascending aorta exceeding the upper limit of normal for age, sex, and body surface area (≥ 4.0 cm as an example of a common threshold; but age, sex and body size-specific thresholds have been established for the aortic root24 and ascending aorta25); no antihypertensive use or stable antihypertensive regimen ≥ 4 weeks; eGFR ≥ 50 mL/min/1.73 m²; serum potassium ≤ 5.1 mmol/L; ability to provide informed consent.
Exclusion: prior aortic surgery, endovascular repair, or acute aortic syndrome; Heritable aortopathies (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndromes; familial TAA, genetically-proven TAA); major peripheral artery disease affecting the carotids, iliacs and/or external femoral arteries precluding cfPWV measurement; bicuspid aortic valve; inflammatory aortitis,; permanent atrial fibrillation/flutter; current use of spironolactone, eplerenone or finererone; pregnancy or lactation.